Documente Academic
Documente Profesional
Documente Cultură
WILBERT S. ARONOW, M.D., MARK LURIE, M.D., MARVIN TURBOW, M.D., PH.D.,
KENNETH WHITTAKER, PHARM. D., M.D., STEVEN VAN CAMP, M.D.,
AND DAVID HUGHES, M.D.
SUMMARY The effect of the vasodilator prazosin vs placebo on exercise duration until marked dyspnea,
and on left ventricular function measured by echocardiography, was evaluated in a double-blind, randomized
study in 24 patients with chronic left ventricular failure despite digitalis and diuretic therapy. Compared with
the double-blind placebo, prazosin reduced resting systolic and diastolic blood pressure and systolic blood
pressure times heart rate, improved clinical symptoms, decreased cardiothoracic ratio measured by chest
roentgenography, decreased left ventricular and left atrial dimensions, improved ejection fraction and Vcf
measured by echocardiography, and improved treadmill exercise duration. All 12 patients taking prazosin had
> 20% improved treadmill exercise duration; none of 12 receiving placebo improved. In six of 12 patients taking prazosin, roentgenographic evidence of pulmonary venous congestion disappeared compared with none of
the patients on placebo. These data suggest that prazosin may be effective in treating chronic left ventricular
failure.
ORAL, SUBLINGUAL AND TOPICAL vasodilators are important in the management of severe heart
failure.' '7 By reducing ventricular preload, nitrates
relieve pulmonary congestion.'`8 By reducing ventricular afterload, oral hydralazine improves cardiac output." 8-12
A combination of nitrates and hydralazine may
relieve dyspnea by reducing pulmonary congestion
and decrease fatigue by increasing cardiac output.5, 8
However, chronic hydralazine therapy may be
associated with induction of the systemic lupus
erythematosus syndrome.
Oral prazosin has balanced vasodilator effects on
the systemic arterial and venous beds.'2-55 Preliminary
data also show that prazosin improves exercise duration and echocardiographic measurements of ventricular function.15
We performed a double-blind, randomized study to
evaluate the effect of prazosin vs placebo on treadmill
exercise performance and on ventricular function,
measured by echocardiography, in 24 patients with
chronic left-sided congestive heart failure unresponsive to digitalis and diuretic therapy.
Methods
The subjects were 24 men 26-67 years of age with
chronic left-sided congestive heart failure. Fifteen had
documented coronary heart disease. Cardiac
catheterization demonstrated significant multivessel
coronary artery disease and poor left ventricular function in these subjects. Thirteen of the 15 patients with
From the Cardiology Section, Long Beach Veterans Administration Hospital, and the University of California College of Medicine.
Irvine, California.
Address for reprints: Wilbert S. Aronow, M.D., Veterans Administration Hospital. Long Beach, California 90822.
Received April 27, 1978; revision accepted September 13, 1978.
Circulation 59, No. 2, 1979.
344
Downloaded from http://circ.ahajournals.org/ by guest on April 7, 2016
345
SV = LVEDV- LVESD
ci heart rate X SV
1,000 X body surface area
EF - SV
=
LVEDV
CIRCULATION
346
TABLE 1. Hemodynamic Values, Exercise Duration, ST-Segment Depression and Cardiothoracic Ratio During Baseline, SingleBlind Placebo and Double-Blind Placebo Periods (Mean 1 SD)
Single-blind
Double-blind placebo
placebo
3 Weeks
6 Weeks
84.1 i10.4
85.1 i7.6
84.1 = 10.4
Resting heart rate (beats/min)
10.1
125.7 9.2
127.3
126.2 9.9
Resting systolic blood pressure (mm Hg)
82.4
84.2 7.4
6.5
83.7 8.3
Resting diastolic blood pressure (mm Hg)
14.0
107.1
107.3
17.0
106.2
Resting systolic pressure times heart rate/100
16.1
Exercise heart rate (beats/min)
133.6 - 14.5
133.5 + 13.2
134.2
14.8
Exercise systolic blood pressure (mm Hg)
149.2 - 13.2
13.4
149.8
149.2
13.7
Exercise diastolic blood pressure (mm Hg)
90.4 - 5.9
90.5 +7.0
90.3 6.0
Exercise systolic pressure times heart rate/100
198.8 = 22.8
199.6 23.9
199.5 20.8
Exercise duration (sec)
221.2 - 59.7
218.7 54.5
224.4 60.5
Maximal ST depression below resting level (mm)
1.48 - 0.45
1.48 0.44
1.50 0.44
Cardiothoracic ratio
0.58 - 0.04
0.58 f0.04
0.58 +0.04
had
Eight patients
coronary heart disease; two had congestive cardiomyopathy; two had rheumatic heart disease with severe
mitral insufficiency and poor left ventricular function.
Parameter
Baseline
83.8 9.9
124.2
11.8
82.3
8.4
104.2
16.9
133.1 l 14.0
148.7 - 12.5
90.0 - 6.6
197.4 - 22.6
211.9 - 56.0
1.42 = 0.47
0.58 = 0.04
Figure 2 shows the percent change in exercise duration for each patient after 6 weeks of double-blind
placebo therapy from the average of the baseline and
single-blind placebo periods. None of the 12 patients
randomized to double-blind placebo had > 20% improvement in exercise duration.
Table 3 lists the echocardiographic data during the
baseline period, after 2 weeks of single-blind placebo,
and after 3 and 6 weeks of double-blind placebo. Table
4 indicates the same data for the baseline period, after
2 weeks of single-blind placebo, after 3 weeks of
TABLE 2. Hemodynantic Values, Exercise Duration, ST-Segment Depression and Cardiothoracic Ratio During Baseline, SingleBlind Placebo and Prazosin Periods (Mean 1 sD)
Double-blind prazosin
Single-blind
Baseline
placebo
3 Weeks
6 Weeks
=
i
Resting heart rate (beats/min)
90.3 = 11.2
89.6 9.5
86.7 8.2
86.8 = 7.3
Resting systolic blood pressure (mm Hg)
122.8 d 8.8
124.7 d 9.2
113.3 7.9*
108.5 7.8*
Resting diastolic blood pressure (mm Hg)
83.0 7.5
83.0 6.5
75.6 i 6.1*
72.3
6.4*
Resting systolic pressure times heart rate/100
110.8
14.3
111.6
13.7
98.2
94.3
10.9*
lil.t
Exercise heart rate (beats/min)
129.2 - 10.2
131.3 - 9.7
131.1 - 9.1
133.2 - 10.1
Exercise systolic blood pressure (mm Hg)
148.7 - 11.2
149.8 - 13.2
147.7 - 11.6
147.9 - 12.6
Exercise diastolic blood pressure (mm Hg)
88.3 - 8.3
88.8 = 8.5
87.5 - 7.6
86.8 - 7.7
Exercise systolic pressure times heart rate/100
192.4 = 24.6
197.2 - 26.6
193.9 - 23.6
197.3 - 26.0
Exercise duration (sec)
213.3 - 54.9
223.4 - 59.0
291.7 - 71.8t
342.1 - 81.4*
Maximal ST depression below resting level (mm)
1.42 = 0.25
1.37 - 0.25
1.24
0.26
1.33 - 0.27
Cardiothoracic ratio
0.58 i 0.04
0.57 *0.04
0.56 i 0.04t
0.58 - 0.04
*p <0.001 for prazosin at 3 weeks minus an average of its baseline and single-blind placebo periods, compared with doubleblind placebo at 3 weeks minus an average of its baseline and single-blind placebo periods; or for prazosin at 6 weeks minus an
average of its baseline and single-blind placebo periods, compared with double-blind placebo at 6 weeks minus an average of its
baseline and single-blind placebo periods.
tP <0.005 for prazosin at 3 weeks minus an average of its baseline and single-blind placebo periods, compared with doubleblind placebo at 3 weeks minus an average of its baseline and single-blind placebo periods; or for prazosin at 6 weeks minus an
average of its baseline and single-blind placebo periods, compared with double-blind placebo at 6 weeks minus an average of its
baseline and single-blind placebo periods.
tp <0.01 for prazosin at 3 weeks minus an average of its baseline and single-blind placebo periods, compared with double-bliind
placebo at 3 weeks minus anl average of its baseline and single-blind placebo periods.
Seven patients had coronary heart disease; five had congestive cardiomyopathy.
Parameter
347
z
0
90-
<
C)
+
80-
+20+16 +1 2+ 8+ 4-
0-
70*
0
co
z
I
+ 60-
CD
S'
0
z
50-
_-n
I
10
12
PATIENT NUMBER
4- 8-12-16-
0
w
40-
-0
0+
30-
20-
PATIENT NUMBER
FIGURE 1. Percent change in exercise duration for each
patient after 6 weeks of prazosin therapy from average of
baseline and single-blind placebo periods.
Discussion
Prazosin has been shown to cause a prolonged dilating action on both the arterial and venous systems.2' 14
As a result, it relieves congestive heart failure by
reducing left ventricular filling pressure and by reducing impedance with augmentation of cardiac output.'2' 14 The studies by Miller and associates14 and
TABLE 3. Echocardiographic Data During Baseline, Single-Blind Placebo and Double-Blind Placebo Periods
(Mean - 1 SD)
Double-blinid placebo
Single-blind
3 Weeks
6 Weeks
placebo
Baseline
Parameter
5.5 - 0.9
5.5 0.9
5.5 0.9
5.5 0.9
LVEDD (cm)
4.6 - 0.9
4.5
0.9
4.6 0.9
4.5 - 0.9
LVESD (cm)
4.4 0.8
4.4 0.8
4.4 0.8
4.3 0.7
LAD (cm)
238.3 32.8
237.5 34.5
235.0 29.7
237.9 29.2
Systolic ejection time (msec)
30.3
72.8 28.2
73.3
34.1
75.8
75.5 31.6
Stroke volume (ml)
1.22
3.13
3.14 = 1.25
3.26
1.42
1.49
3.28
Cardiac index (1/min/m2)
42.3
8.6
44.2
(%)
8.9
9.0
9.4
43.7
44.5
fraction
Ejection
0.15
0.71
0.75 - 0.16
0.75 0.17
0.76 0.19
Vcf (circ/sec)
Abbreviations: LVEDD = left ventricular dimension at end-diastole; LVESD = left ventricular dimension at end-systole; LAD = left atrial dimension; Vcf = mean rate of left ventricular circumferential fiber
shortening.
Downloaded from http://circ.ahajournals.org/ by guest on April 7, 2016
CIRCULATION
348
TAB3LE 4. Echocardiographic Data During Baseline, Single-Blind Placebo and Double-Blind Prazosin Periods
(Mean 1 SD)
Double-blind prazosin
Single-blind
6 Weeks
3 Weeks
Baseline
placebo
0.6
6.2
6.4
0.5
6.4
6.5 0.6
0.61
5.7 0 R5
5.4 0.6*
5.7 - 0.6
5.5 - 0.6
4.2
4.4 0.6
4.3
4.5 0.6
0.6t
0.51
230.0 33.2
227.1
228.8 i 25.1
24.7
229.2 26.4
82.8 i 23.0
88.4 i 19.3
87$i~ 24.8
85.3 - 21.7
3.90
3.84 i 1.26
3.79 1.30
1.29
3.95 M 1.08
4
36.2
31.6 4.9
34.4 i 5.1
30.8 7.0
6.9t
0.51 i 0.12
0.52 i 0.10
0.58 =fi 0.10
0.62 0.13*
*p <0.001 for prazosin at 6 weeks minius an average of its baseline and single-blind placebo periods,
compared with double-blind placebo at 6 weeks minus an average of its baseltine and single blind placebo
periods.
tP <0.005 for prazosin at 6 weeks minus an average of its baseline and single-blind placebo periods, compared with double-blind placebo at 6 weeks minus an average of its baseline and single-blinid placebo periods.
lp <0.05 for prazosin at 3 weeks minus an average of its baseline and single-blinid placebo periods, compared with double-blind placebo at 3 weeks minus an average of its baseline and single-blind placebo periods;
or for prazosin at 6 weeks rninus an average of its baseline and single-blind placebo periods, compared with
double-blind placebo at 6 weeks minius aII average of its baseline and single-blind placebo periods.
Abbreviatioins: LVEDD left ventricular dimension at end-diastole; LVESI) left ventricular dimension at end-systole; LAD left atrial dimension: Vef = mean rate of left venitricular circumferential fiber
shortening.
Parameter
LVEDD (cm)
LVESD (cm)
LAD (cm)
Syst olic ejection time (msec)
Stroke volume (ml)
Cardiac index (1/min/M2)
Ejection fraction (C/0)
Vcf (circ/sec)
349
Acknowledgment
We thank David S. Salsburg, Ph.D., for biostatistical analysis of
the data and Colin R. Taylor, M.B., Pfizer, Inc., for supplying the
prazosin and placebo.
References
I. Franciosa JA, Mikulic E, Cohn JN, Jose E, Fabie A:
2.
3.
4.
5.
6.
ventricular
sion and
relative to
responsible
7.
8.
9.
prazosin.
There were baseline inequalities in echocardiographic measurements of EF, LVEDD, LVESD, and
Vcf between the prazosin and double-blind placebo
groups. The results of the single-blind placebo intervention in both the prazosin and double-blind placebo
groups support the conclusion that these baseline inequalities did not influence the therapeutic response to
prazosin. However, to correct for these baseline imbalances, we compared prazosin and double-blind
placebo withinr the framework of a one-way analysis of
covariance. This analysis showed that these baseline
inequalities did not alter our conclusions regarding
beneficial effects of prazosin vs double-blind placebo
on clinical symptoms, blood pressure, exercise performance, cardiothoracic ratio, pulmonary venous congestion, and left ventricular dimensions and function.
While the combination of hydralazine with longacting nitrates may relieve pulmonary congestion and
increase cardiac output,57 oral prazosin has the advantage of a single drug accomplishing the same
thing.'12 23 Moreover, prazosin does not have the
disadvantage of hydralazine's side effects.
Further data should define the role of vasodilating
drugs in the chronic treatment of left ventricular
10.
11.
12.
13.
14.
l5.
16.
350
CIRCULATION
cavitary size and cardiac performance determined by ultrasound in man. Am J Med 57: 754, 1974
21. Prakash R, Aronow WS, Warren M, Laverty W, Gottschalk
LA: Effects of marihuana and placebo marihuana smoking on
hemodynamics in coronary disease. Clin Pharmacol Ther 18:
90, 1975
22. Cooper R, O'Rourke JS, Karliner RA, Peterson KL, Leopold
GR: Comparison of ultrasound and cineangiographic measurements of the rate of circumferential fiber shortening in man.
Circulation 46: 914, 1972
23. Braunwald E: Vasodilator therapy - a physiologic approach to
the treatment of heart failure. N Engl J Med 297: 331, 1977
AND
SUMMARY Deep venous thrombosis (DVT) of the upper extremity is an unusual thrombotic event (1-2%
of all DVT) which can be conveniently divided into two categories, traumatic (including "stress") and spontaneous. The spontaneous form is not reported as often in the literature, but occurs more commonly than the
traumatic form. There is an increased left-sided predominance in spontaneous DVT compared with the
traumatic form, where a right-sided predominance exists. Possible anatomical and physiological explanations
are offered for the left-sided predominance in spontaneous DVT of the upper extremity. The thrombogenesis of
DVT of the upper extremity is compared with DVT of the lower extremity. An analysis of responses to
therapy and considerations for other therapeutic approaches are offered.
84148.
Received April 5, 1978; revision accepted September 26, 1978.
Circulation 59, No. 2, 1979.
The online version of this article, along with updated information and services, is located on
the World Wide Web at:
http://circ.ahajournals.org/content/59/2/344
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally
published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the
Editorial Office. Once the online version of the published article for which permission is being requested is
located, click Request Permissions in the middle column of the Web page under Services. Further
information about this process is available in the Permissions and Rights Question and Answer document.
Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints
Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/